Cargando…

Effect of umifenovir (arbidol) versus standard care on clinical outcome in patients with COVID-19: a retrospective cohort study

BACKGROUND: Coronavirus disease 2019 (COVID-19) continues to spread quickly throughout the world, mainly due to the lack of effective drug therapies and vaccines. The effectiveness of the antiviral drug umifenovir needs to be further clarified. METHODS: This retrospective cohort study included 1254...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Wanwan, Jia, Chengyou, Yang, Ziyu, Fan, Hengwei, Li, Ming, Lv, Zhongwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328169/ https://www.ncbi.nlm.nih.gov/pubmed/37395539 http://dx.doi.org/10.1177/17534666231183811

Ejemplares similares

Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
por: Nojomi, Marzieh, et al.
Publicado: (2020)

Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis
por: Amani, Behnam, et al.
Publicado: (2021)

Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses
por: Haviernik, Jan, et al.
Publicado: (2018)

Antiviral drug Umifenovir (Arbidol) in municipal wastewater during the COVID-19 pandemic: Estimated levels and transformation
por: Ul'yanovskii, Nikolay V., et al.
Publicado: (2022)

Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19
por: Liu, Lei, et al.
Publicado: (2021)

Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19
por: Choudhary, Shalki, et al.
Publicado: (2020)

Antioxidant Potential of Antiviral Drug Umifenovir
por: Proskurnina, Elena V., et al.
Publicado: (2020)

Risk factors for recurrent positive results of the nucleic acid amplification test for COVID-19 patients: a retrospective study
por: Yi, Wanwan, et al.
Publicado: (2021)

Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study
por: Lian, N., et al.
Publicado: (2020)

Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma
por: Wang, Ru, et al.
Publicado: (2022)

Efficacy of arbidol in COVID-19 patients: A retrospective study
por: Wei, Shuo, et al.
Publicado: (2021)

The regulation role and diagnostic value of fibrinogen-like protein 1 revealed by pan-cancer analysis
por: Yi, Wanwan, et al.
Publicado: (2022)

Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission: A Preliminary Report of a Retrospective Cohort Study
por: Zhang, Jin-nong, et al.
Publicado: (2020)

An 8 miRNA-Based Risk Score System for Predicting the Prognosis of Patients With Papillary Thyroid Cancer
por: Yi, Wanwan, et al.
Publicado: (2020)

Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study
por: Xu, Ping, et al.
Publicado: (2020)

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
por: Deng, Lisi, et al.
Publicado: (2020)

Moxifloxacin/umifenovir: Pancytopenia and off label use: case report
Publicado: (2021)

Beneficial effect of Arbidol in the management of COVID-19 infection
por: Jie, Xiong, et al.
Publicado: (2021)

A trial of arbidol hydrochloride in adults with COVID-19
por: Zhao, Jingya, et al.
Publicado: (2022)

The Antiviral Drug Arbidol Inhibits Zika Virus
por: Fink, Susan L., et al.
Publicado: (2018)

Arbidol as a broad-spectrum antiviral: An update
por: Blaising, Julie, et al.
Publicado: (2014)

Arbidol: The current demand, strategies, and antiviral mechanisms
por: Kang, Yue, et al.
Publicado: (2023)

Reinforcing the supply chain of umifenovir and other antiviral drugs with retrosynthetic software
por: Lin, Yingfu, et al.
Publicado: (2021)

Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study
por: Fang, Jie, et al.
Publicado: (2020)

Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals
por: Yang, Chunguang, et al.
Publicado: (2020)

Clinical implications of different specimen types for nucleic acid testing in two cases of COVID-19
por: Fan, Hengwei, et al.
Publicado: (2020)

Immune globulin/umifenovir: Off-label use and lack of efficacy: case report
Publicado: (2021)

Moxifloxacin/umifenovir: Lack of efficacy following off-label use: case report
Publicado: (2021)

Methylprednisolone/umifenovir interaction: Sinus bradycardia and off label use: case report
Publicado: (2022)

Umifenovir Epigenetically Targets the IL-10 Pathway in Therapy against Coxsackievirus B4 Infection
por: Zhang, Shilin, et al.
Publicado: (2022)

Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
por: Alavi Darazam, Ilad, et al.
Publicado: (2021)

Author Correction: Reinforcing the supply chain of umifenovir and other antiviral drugs with retrosynthetic software
por: Lin, Yingfu, et al.
Publicado: (2022)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Synthesis and biological activity of water-soluble polymer complexes of arbidol
por: Eropkin, M. Yu., et al.
Publicado: (2010)

Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice
por: Li, Hailong, et al.
Publicado: (2021)

Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study
por: Yin, Peng, et al.
Publicado: (2021)

The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies
por: Fan, Hengwei, et al.
Publicado: (2017)

Meropenem/moxifloxacin/umifenovir: QT interval prolongation and off label use: 2 case reports
Publicado: (2021)

Lopinavir/ritonavir/umifenovir: Nausea, vomiting and diarrhoea following off-label treatment: case report
Publicado: (2021)

Mechanism of Inhibition of Enveloped Virus Membrane Fusion by the Antiviral Drug Arbidol
por: Teissier, Elodie, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_adg7i8dlf4vcj0j119bt4f37tj